Advertisement

Specialty News

June 19, 2017
June 19, 2017
The Oral Rheumatoid Arthritis trial (ORAL) Strategy assessed the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and...
The Oral Rheumatoid Arthritis trial (ORAL) Strategy assessed the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate.
MORE
June 19, 2017
June 19, 2017
Clovis Oncology Inc said its ovarian cancer drug rucaparib camsylate (Rubraca) slowed disease progression in a late-stage trial involving patients...
Clovis Oncology Inc said its ovarian cancer drug rucaparib camsylate (Rubraca) slowed disease progression in a late-stage trial involving patients with various gene mutations who had undergone initial therapy.
MORE
June 09, 2017
June 09, 2017
Some prominent cancer doctors plan to use clinical trials to show that many oncology medications could be taken at lower doses or for shorter...
Some prominent cancer doctors plan to use clinical trials to show that many oncology medications could be taken at lower doses or for shorter periods without hurting their effectiveness. A pilot study by the group of doctors involving a widely prescribed drug for advanced prostate cancer.
MORE
June 06, 2017
June 06, 2017
Researchers are optimistic about the potential for the new cancer drug larotrectinib—which promises to help patients, young and old, who are...
Researchers are optimistic about the potential for the new cancer drug larotrectinib—which promises to help patients, young and old, who are suffering from a wide range of diagnoses.
MORE
June 06, 2017
June 06, 2017
New research indicates that for women with HER2-positive, operable breast cancer, pertuzumab increased the rates of invasive-disease–free survival...
New research indicates that for women with HER2-positive, operable breast cancer, pertuzumab increased the rates of invasive-disease–free survival when added to trastuzumab and chemotherapy.
MORE
June 05, 2017
June 06, 2017
The American Pharmacists Association (APhA) convened the Biologics and Biosimilars Stakeholder Conference on November 30, 2016, in Washington DC....
The American Pharmacists Association (APhA) convened the Biologics and Biosimilars Stakeholder Conference on November 30, 2016, in Washington DC. The objectives of the Conference were to determine the key issues and challenges within the marketplace for biologics, follow-on biologics (FOBs), and biosimilars, identify potential roles and responsibilities of pharmacists regarding biologic and biosimilar medications, and identify actions or activities that pharmacists may take to optimize the safe and cost-effective use of biologics and biosimilars.
MORE
May 25, 2017
May 25, 2017
For patients who have recently undergone an organ transplant, medication adherence is critical. That is why two pharmacists at NewYork-Presbyterian...
For patients who have recently undergone an organ transplant, medication adherence is critical. That is why two pharmacists at NewYork-Presbyterian Hospital decided to start seeing patients virtually, enabling them to maintain continuity of care after discharge from the hospital.
MORE
May 23, 2017
May 23, 2017
Pharmacists can fill a gap in care by expanding their injectable medication administration services beyond immunization, according to a report...
Report of Stakeholder Conference on Improving Patient Access to Injectable Medications available online in JAPhA
MORE
May 23, 2017
May 23, 2017
FDA expanded on Monday the approved use of subcutaneous tocilizumab (Actemra—Hoffman La Roche) to treat adults with giant cell arteritis, providing...
FDA expanded on Monday the approved use of subcutaneous tocilizumab (Actemra—Hoffman La Roche) to treat adults with giant cell arteritis, providing the first FDA-approved therapy specific to this type of vasculitis.
MORE
May 18, 2017
May 18, 2017
FDA expanded on Wednesday the approved use of ivacaftor (Kalydeco—Vertex Pharmaceuticals) for treating cystic fibrosis. The decision expands the...
FDA expanded on Wednesday the approved use of ivacaftor (Kalydeco—Vertex Pharmaceuticals) for treating cystic fibrosis. The decision expands the number of rare gene mutations that the drug can now treat from 10 mutations to 33.
MORE

Pages